OmniAb, Inc. has officially launched the xPloration® Partner Access Program, allowing its existing partners to purchase the proprietary xPloration instrument—a powerful, AI-driven single B-cell screening platform designed to significantly enhance antibody discovery and development. This platform, which has been integral to OmniAb’s internal operations, offers partners direct access to cutting-edge technology featuring high-throughput screening, improved hit recovery, and simplified user operation, thereby accelerating the discovery of rare antibodies.

The xPloration system distinguishes itself through its 1.5 million microcapillary chip design, laser-based cell recovery, and fluidics-free interface, enabling rapid processing times and superior screening performance over traditional methods like hybridoma or FACS. These features allow for the recovery of thousands of antibody variants in just hours, expanding diversity, specificity, and affinity—crucial for discovering effective therapeutic candidates. The platform’s commercial release follows extensive validation and demand from nearly 100 partners, marking a new revenue stream and expanding OmniAb’s market footprint.

OmniAb plans to highlight the capabilities of xPloration at the 21st Annual PEGS Boston Summit, including presentations by internal experts and partners like Antibody Solutions, the first external user of the platform. The program demonstrates OmniAb’s commitment to democratizing access to its advanced technologies, enhancing partner research productivity, and reinforcing its role as a leader in antibody discovery innovation. For more information, interested parties are encouraged to contact OmniAb’s business development team.